EUVIMEDEUVIMED entdecken
CrossrefInfokarte

GINS complex couples DNA replication stress to therapeutic resistance in hepatocellular carcinoma

Hao-Wen Yang, Xi Chen, Wen-Jie Wu, Liu Yang, Xing-Bao Fang

World Journal of Gastrointestinal Oncology · 2026-11-15 · 18 (11)

DOI: 10.4251/wjgo.124074 ↗
AbstractBibliografische Angaben

Abstract

DNA replication stress is a central molecular event in tumorigenesis and cancer progression. As an essential component of the eukaryotic replisome, the GINS complex, composed of GINS1/PSF1, GINS2/PSF2, GINS3/PSF3, and GINS4/ SLD5, cooperates with CDC45 and MCM2-7 to form the Cdc45-MCM-GINS helicase, which drives replication initiation and fork elongation. Aberrant expression of GINS subunits has been linked to cell-cycle activation, genomic instability, epithelial-mesenchymal transition, cancer stemness, immune microenvironment remodeling, and therapeutic resistance. Hepatocellular carcinoma (HCC) remains a major global health burden, with approximately 685000 new cases and 597000 deaths worldwide in 2022, and resistance to immune checkpoint inhibitor-based combinations, dual immunotherapy, and multitarget tyrosine kinase inhibitors continues to limit durable clinical benefit. This minireview summarizes the biological roles of the GINS complex and DNA replication stress in tumor progression, stemness, and therapeutic resistance, with a focus on their translational relevance in HCC. Current HCC evidence mainly implicates GINS1, GINS2, and GINS4, including the emerging GINS4/POLE2/ferroptosis axis, whereas GINS3 remains insufficiently validated. Therefore, the GINS-CMG axis should be regarded as a candidate biomarker and hypothesis-generating therapeutic concept rather than an established causal driver in HCC.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →